Sign up for the email list

Thank you for providing a training for Mitchell/Thames Academy. Each time I see one of your presentations I learn something new, a sign of an excellent... Stacey A. Torpey LPC, NCC Mitchell College

New generic versions of Keppra XR

Yesterday and today two new anti-epileptic drugs were announced. They are both generic versions of UCB, Inc.'s Keppra XR®. Keppra XR® is indicated for adjunctive therapy to treat partial onset seizures in patients with epilepsy who are 16 years of age and older.

Watson Pharmaceuticals, Inc. announced yesterday that its subsidiary, Watson Laboratories, Inc. has launched Levetiracetam extended-release 500 mg and 750 mg tablets, following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson began shipping the product yesterday.

Pharmaceutical company, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (LPI) has been granted final approval by the U.S. Food and Drug Administration (FDA) for the company’s Abbreviated New Drug Application (ANDA) to market Levetiracetam 500 mg and 750 mg extended-release tablets that are the AB-rated generic equivalent of Keppra XR®. Commercial shipment of the product has commenced.

For information regarding medications as a treatment for epilepsy, please visit our Medications page:
For more information on Watson, visit their website and for more information on Lupin, visit their website


Back To All News
Home      About Us      Events      News      Programs and Services      Photos      Advocacy      Epilepsy Facts      Volunteers      Research      Contact Us

© 2015 Epilepsy Foundation Connecticut   |   (860) 346-1924 or (800) 899-3745   |   386 Main St Middletown, CT, 06457-3360   |  en español

Creative Sunrise Web Development